Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK

HIV Clin Trials. 2012 Jul-Aug;13(4):228-32. doi: 10.1310/hct1304-228.

Abstract

We compared 4 years of antiretroviral therapy with tenofovir/emtricitabine and either raltegravir or efavirenz from the ongoing STARTMRK study of treatment-naïve HIV-infected patients. Through 192 weeks, raltegravir produced durable and consistent viral suppression and immune restoration compared with efavirenz irrespective of baseline demographic and prognostic factors, including in patients with high viral loads.

Trial registration: ClinicalTrials.gov NCT00369941.

Publication types

  • Clinical Trial, Phase III
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy*
  • Acquired Immunodeficiency Syndrome / immunology
  • Acquired Immunodeficiency Syndrome / virology
  • Adenine / administration & dosage
  • Adenine / analogs & derivatives
  • Adolescent
  • Adult
  • Aged
  • Alkynes
  • Anti-HIV Agents / administration & dosage*
  • Benzoxazines / administration & dosage
  • CD4 Lymphocyte Count
  • Cyclopropanes
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Drug Resistance, Viral
  • Drug Therapy, Combination
  • Emtricitabine
  • Female
  • HIV-1*
  • Humans
  • Male
  • Middle Aged
  • Organophosphonates / administration & dosage
  • Pyrrolidinones / administration & dosage
  • Raltegravir Potassium
  • Tenofovir

Substances

  • Alkynes
  • Anti-HIV Agents
  • Benzoxazines
  • Cyclopropanes
  • Organophosphonates
  • Pyrrolidinones
  • Deoxycytidine
  • Raltegravir Potassium
  • Tenofovir
  • Emtricitabine
  • Adenine
  • efavirenz

Associated data

  • ClinicalTrials.gov/NCT00369941